INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2017

A review notes that unlike preclinical studies, human studies show resveratrol cannot protect against metabolic diseases and associated complications.

This review evaluates preclinical and clinical findings on the dietary polyphenol resveratrol regarding its dose, absorption, interactions, toxicity, and therapeutic effects against chronic conditions. A comparison of animal and human studies indicates that resveratrol cannot protect against metabolic diseases and their related complications. The authors note that clinical outcomes are influenced by factors such as sample size.

Study type
Narrative review
Who was studied
Human and animal studies
What was measured
Metabolic and chronic disease outcomes, dose, absorption, and toxicity

THE PAPER

Significance of Resveratrol in Clinical Management of Chronic Diseases.

Wahab A, Gao K, Jia C, Zhang F, Tian G, Murtaza G, Chen J. Molecules, 2017.

PubMed 28820474 ↗DOI 10.1002/mnfr.201100117 ↗

Heart & arteriesDiabetes & blood sugarCancerWeight & appetiteHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.